The Multidimensional Challenge of Treating Coronavirus Disease 2019 (COVID-19) : Remdesivir Is a Foot in the Door
| Errataetall: |
CommentOn: Clin Infect Dis. 2021 Dec 6;73(11):e4166-e4174. - PMID 32706859 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 73(2021), 11 vom: 06. Dez., Seite e4175-e4178 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gandhi, Rajesh T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3QKI37EEHE |
|---|
| Anmerkungen: |
Date Completed 13.12.2021 Date Revised 07.12.2022 published: Print CommentOn: Clin Infect Dis. 2021 Dec 6;73(11):e4166-e4174. - PMID 32706859 Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciaa1132 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313111464 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313111464 | ||
| 003 | DE-627 | ||
| 005 | 20231225145850.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciaa1132 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1043.xml |
| 035 | |a (DE-627)NLM313111464 | ||
| 035 | |a (NLM)32735655 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gandhi, Rajesh T |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Multidimensional Challenge of Treating Coronavirus Disease 2019 (COVID-19) |b Remdesivir Is a Foot in the Door |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.12.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: Clin Infect Dis. 2021 Dec 6;73(11):e4166-e4174. - PMID 32706859 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a dexamethasone | |
| 650 | 4 | |a remdesivir | |
| 650 | 4 | |a treatment | |
| 650 | 7 | |a remdesivir |2 NLM | |
| 650 | 7 | |a 3QKI37EEHE |2 NLM | |
| 650 | 7 | |a Adenosine Monophosphate |2 NLM | |
| 650 | 7 | |a 415SHH325A |2 NLM | |
| 650 | 7 | |a Alanine |2 NLM | |
| 650 | 7 | |a OF5P57N2ZX |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 73(2021), 11 vom: 06. Dez., Seite e4175-e4178 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2021 |g number:11 |g day:06 |g month:12 |g pages:e4175-e4178 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciaa1132 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2021 |e 11 |b 06 |c 12 |h e4175-e4178 | ||